These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32783701)

  • 1. Protection against
    Guibinga GH; Sahay B; Brown H; Cooch N; Chen J; Yan J; Reed C; Mishra M; Yung B; Pugh H; Schultheis K; Esquivel RN; Weiner DB; Humeau LH; Broderick KE; Smith TRF
    Hum Vaccin Immunother; 2020 Sep; 16(9):2114-2122. PubMed ID: 32783701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel multi-protein chimeric immunogens that protect against infection with the Lyme disease agent,
    O'Bier NS; Camire AC; Patel DT; Billingsley JS; Hodges KR; Marconi RT
    mBio; 2024 Oct; 15(10):e0215924. PubMed ID: 39287439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tick-Tattoo: DNA Vaccination Against
    Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
    Front Immunol; 2021; 12():615011. PubMed ID: 33717102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Elucidation of a Protective B Cell Epitope on Outer Surface Protein C (OspC) of the Lyme Disease Spirochete, Borreliella burgdorferi.
    Rudolph MJ; Davis SA; Haque HME; Weis DD; Vance DJ; Piazza CL; Ejemel M; Cavacini L; Wang Y; Mbow ML; Gilmore RD; Mantis NJ
    mBio; 2023 Apr; 14(2):e0298122. PubMed ID: 36976016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.
    de Silva AM; Telford SR; Brunet LR; Barthold SW; Fikrig E
    J Exp Med; 1996 Jan; 183(1):271-5. PubMed ID: 8551231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agglutination of Borreliella burgdorferi by Transmission-Blocking OspA Monoclonal Antibodies and Monovalent Fab Fragments.
    Frye AM; Ejemel M; Cavacini L; Wang Y; Rudolph MJ; Song R; Mantis NJ
    Infect Immun; 2022 Sep; 90(9):e0030622. PubMed ID: 36000876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A.
    Shang ES; Champion CI; Wu XY; Skare JT; Blanco DR; Miller JN; Lovett MA
    Infect Immun; 2000 Jul; 68(7):4189-99. PubMed ID: 10858236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
    Izac JR; Oliver LD; Earnhart CG; Marconi RT
    Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Surface Epitopes Associated with Protection against Highly Immune-Evasive VlsE-Expressing Lyme Disease Spirochetes.
    Batool M; Caoili SEC; Dangott LJ; Gerasimov E; Ionov Y; Piontkivska H; Zelikovsky A; Waghela SD; Rogovskyy AS
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29866906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of a transmission blocking antibody in complex with Outer surface protein A from the Lyme disease spirochete, Borreliella burgdorferi.
    Rudolph MJ; Davis SA; Haque HME; Ejemel M; Cavacini LA; Vance DJ; Willsey GG; Piazza CL; Weis DD; Wang Y; Mantis NJ
    Proteins; 2023 Nov; 91(11):1463-1470. PubMed ID: 37455569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
    Luke CJ; Carner K; Liang X; Barbour AG
    J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis.
    Klouwens MJ; Trentelman JJ; Ersoz JI; Nieves Marques Porto F; Sima R; Hajdusek O; Thakur M; Pal U; Hovius JW
    Sci Rep; 2021 Feb; 11(1):4775. PubMed ID: 33637813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
    Comstedt P; Schüler W; Meinke A; Lundberg U
    PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
    Zhong W; Gern L; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.